Grants and Contributions:
Title:
Novel Payloads for Antibody-Drug Conjugates in Precision Cancer Therapeutics
Agreement Number:
1042859
Agreement Value:
$137,000.00
Agreement Date:
Apr 1, 2026 - Mar 31, 2027
Description:
This project will develop novel potent and DNA repair kinase inhibitors as payloads for antibody-drug conjugates, aiming to selectively target defective pathways in cancers including lung, breast and ovarian.
Organization:
National Research Council Canada
Expected Results:
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Location:
Vancouver, British Columbia, CA V6E 4E5
Reference Number:
172-2026-2027-Q1-1042859
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
763954625
Recipient Type:
For-profit organization
Recipient's Legal Name:
DCx Biotherapeutics Corporation
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program
Program Purpose:
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Coverage:
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity.
NAICS Code:
541710